Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia

Journal of Lipid Research

Volumn 53, Issue 5, 2012, Pages 979-983

  Huijgen, R ^a   Fouchier, S W ^a   Denoun, M ^b   Hutten, B A ^a   Vissers, M N ^a   Lambert, G ^c   Kastelein, J J P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b HEART RESEARCH INSTITUTE   (Australia)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Atherosclerosis; Gene expression; Low density lipoprotein cholesterol; Proprotein convertase subtilisin kexin type 9

Indexed keywords

APOLIPOPROTEIN B; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA DETERMINATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE ACTIVITY; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, LDL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC TESTING; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PHENOTYPE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; YOUNG ADULT;

EID: 84860290100     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P023994     Document Type: Article

References (27)

1. Goldstein, J. L., H. H. Hobbs, and M. S. Brown. 2001. Familial hypercholesterolemia. In The Metabolic and Molecular Bases of Inherited Disease. 8 th edition. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, eds. McGraw-Hill, New York. 2863-2913.
2. Innerarity, T. L., K. H. Weisgraber, K. S. Arnold, R. W. Mahley, R. M. Krauss, G. L. Vega, and S. M. Grundy. 1987. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc. Natl. Acad. Sci. USA. 84: 6919-6923. (Pubitemid 18025501)
3. Abifadel, M., M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34: 154-156. (Pubitemid 36666925)
4. Huijgen, R., M. N. Vissers, J. C. Defesche, P. J. Lansberg, J. J. Kastelein, and B. A. Hutten. 2008. Familial hypercholesterolemia: current treatment and advances in management. Expert Rev. Cardiovasc. Ther. 6: 567-581.
5. Versmissen, J., D. M. Oosterveer, M. Yazdanpanah, J. C. Defesche, D. C. Basart, A. H. Liem, J. Heeringa, J. C. Witteman, P. J. Lansberg, J. J. Kastelein, et al. 2008. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 337: a2423.
6. Umans-Eckenhausen, M. A., J. C. Defesche, E. J. Sijbrands, R. L. Scheerder, and J. J. Kastelein. 2001. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 357: 165-168. (Pubitemid 32108086)
7. Huijgen, R., I. Kindt, S. B. Verhoeven, E. J. Sijbrands, M. N. Vissers, J. J. Kastelein, and B. A. Hutten. 2010. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS ONE. 5: e9220.
8. Lambert, G., F. Charlton, K. A. Rye, and D. E. Piper. 2009. Molecular basis of PCSK9 function. Atherosclerosis. 203: 1-7.
9. Abifadel, M., J. P. Rabes, M. Devillers, A. Munnich, D. Erlich, C. Junien, M. Varret, and C. Boileau. 2009. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum. Mutat. 30: 520-529.
10. Abifadel, M., J. P. Rabes, S. Jambart, G. Halaby, M. H. Gannage-Yared, A. Sarkis, G. Beaino, M. Varret, N. Salem, S. Corbani, et al. 2009. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum. Mutat. 30: E682-E691.
11. Pisciotta, L., O. C. Priore, A. B. Cefalu, D. Noto, A. Bellocchio, R. Fresa, A. Cantafora, D. Patel, M. Averna, P. Tarugi, et al. 2006. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis. 186: 433-440.
12. Huijgen, R., M. N. Vissers, I. Kindt, M. D. Trip, E. de Groot, J. J. Kastelein, and B. A. Hutten. 2011. Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes. Circ. Cardiovasc. Genet. 4: 413-417.
13. Huijgen, R., I. Kindt, S. W. Fouchier, J. C. Defesche, B. A. Hutten, J. J. Kastelein, and M. N. Vissers. 2010. Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia. Hum. Mutat. 31: 752-760.
14. de Groot, E., G. K. Hovingh, A. Wiegman, P. Duriez, A. J. Smit, J. C. Fruchart, and J. J. Kastelein. 2004. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation. 109 (Suppl. 1): III33-III38. (Pubitemid 38786441)
15. Strøm, T. B., O. L. Holla, J. Cameron, K. E. Berge, and T. P. Leren. 2010. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes. Clin. Chim. Acta. 411: 229-233.
16. Huijgen, R., B. Sjouke, K. Vis, J. S. de Randamie, J. C. Defesche, J. J. Kastelein, G. K. Hovingh, and S. W. Fouchier. 2012. Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-C levels. Hum. Mutat. 33: 448-455.
17. Baass, A., G. Dubuc, M. Tremblay, E. E. Delvin, J. O'Loughlin, E. Levy, J. Davignon, and M. Lambert. 2009. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin. Chem. 55: 1637-1645.
18. Cohen, J. C., E. Boerwinkle, T. H. Mosley, and H. H. Hobbs. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354: 1264-1272.
19. Ni, Y. G., J. H. Condra, L. Orsatti, X. Shen, S. Di Marco, S. Pandit, M. J. Bottomley, L. Ruggeri, R. T. Cummings, R. M. Cubbon, et al. 2010. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J. Biol. Chem. 285: 12882-12891.
20. Gupta, N., N. Fisker, M. C. Asselin, M. Lindholm, C. Rosenbohm, H. Orum, J. Elmen, N. G. Seidah, and E. M. Straarup. 2010. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS ONE. 5: e10682.
21. Graham, M. J., K. M. Lemonidis, C. P. Whipple, A. Subramaniam, B. P. Monia, S. T. Crooke, and R. M. Crooke. 2007. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 48: 763-767. (Pubitemid 46557881)
22. Frank-Kamenetsky, M., A. Grefhorst, N. N. Anderson, T. S. Racie, B. Bramlage, A. Akinc, D. Butler, K. Charisse, R. Dorkin, Y. Fan, et al. 2008. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. USA. 105: 11915-11920.
23. Duff, C. J., M. J. Scott, I. T. Kirby, S. E. Hutchinson, S. L. Martin, and N. M. Hooper. 2009. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem. J. 419: 577-584.
24. Chan, J. C., D. E. Piper, Q. Cao, D. Liu, C. King, W. Wang, J. Tang, Q. Liu, J. Higbee, Z. Xia, et al. 2009. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. USA. 106: 9820-9825.
25. Welder, G., I. Zineh, M. A. Pacanowski, J. S. Troutt, G. Cao, and R. J. Konrad. 2010. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J. Lipid Res. 51: 2714-2721.
26. Dubuc, G., A. Chamberland, H. Wassef, J. Davignon, N. G. Seidah, L. Bernier, and A. Prat. 2004. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24: 1454-1459. (Pubitemid 39050440)
27. Careskey, H. E., R. A. Davis, W. E. Alborn, J. S. Troutt, G. Cao, and R. J. Konrad. 2008. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 49: 394-398. (Pubitemid 351213624)